Dec. 5 at 3:14 AM
Commercial-stage oncology focused biopharma valuations as multiples of analyst revenue estimates. The attached table includes all such bios with first approvals since 1/1/20 with market caps between
$750MM &
$5B.
$LEGN is forecast to generate the highest revenue dollars over the next 10 years in this peer group. LEGN sales are trending to north of
$1B/year today.
$SNDX could trade for
$26/share & have an average Year 4 revenue multiple of the group. Listen to SNDX at Evercore today. They are quite confident & bullish. INCY?
$IMCR has traded between
$30 &
$40 a share, more or less, for the last 12 months. IMCR is rising with the XBI but the Phase 3 trials won't read until late next year.
$GERN estimates include meaningful contribution from the MDS label whose Phase 3 trial will not read until next year
This is not investment advice but we believe the market is completely discounting
$IOVA potential in the lung cancer subset. These patients have few options.
Comments welcome
